Table 1.
Quality control of bispecific antibodies (BsAbs).
| BsAb | Recovery after cFAE (%) | Endotoxin (EU/mg) | Monodispersity (%) | Bispecificity (%)* |
|---|---|---|---|---|
| CD19xCD3 IgG1 FES | 92.36 | 0.29 | 95.69 | 94.34 |
| CD19xRSV IgG1 FES | 94.55 | 0.32 | 97.62 | 100.00 |
| RSVxCD3 IgG1 FES | 94.45 | 0.27 | 94.14 | 93.64 |
| CD19xCD3 IgG2 σ1 | 100.67 | 0.27 | 98.87 | 94.33 |
| CD19xRSV IgG2 σ1 | 100.87 | 0.23 | 100.00 | 85.07* |
| RSVxCD3 IgG2 σ1 | 94.95 | 0.26 | 97.93 | 93.43 |
| CD19xCD3 IgG4 PAA | 92.06 | 0.1 | 98.80 | 95.06 |
| CD19xRSV IgG4 PAA | 90.48 | 0.09 | 95.42 | 93.07* |
| RSVxCD3 IgG4 PAA | 91.76 | 0.09 | 96.24 | 96.57 |
| CD19xCD3 IgG1:2 σ1 | 97.94 | 0.04 | 97.94 | 96.66 |
| CD19xRSV IgG1:2 σ1 | 97.19 | 0.08 | 97.19 | 97.60* |
| RSVxCD3 IgG1:2 σ1 | 96.04 | 0.07 | 96.04 | 97.60 |
| CD19xCD3 IgG4:2 σ1 | 97.25 | 0.03 | 97.25 | 100.00 |
| CD19xRSV IgG4:2 σ1 | 98.29 | 0.03 | 98.29 | 95.14* |
| RSVxCD3 IgG4:2 σ1 | 96.71 | 0.03 | 96.71 | 96.04* |
*Molecules whose percentage of bispecificity was characterized by HI-HPLC are indicated with a star. Unmarked molecules were analyzed by CIEX-HPLC.